Special Issue "New Drugs and Biologics For Treatment of Central Nervous Dysfunction"
Deadline for manuscript submissions: closed (15 January 2022).
Interests: astrocytes; neuroprotection; Alzheimer's disease; brain diseases; neurobiology; stem cells; central nervous system; neurodegenerative diseases; neurology
Experimental neuroscience in recent years has brought to light numerous exciting technologies, discoveries of new therapeutic interventions, and molecular targets of CNS disorders. However, many theoretical and practical challenges in establishing novel drugs and biologicals remain when tested in in vivo studies or translated into the clinical use; for example, a number of novel or repurposed compounds have beneficial effects within the central nervous system (CNS), but exert some unwanted side effects, when distributed systemically. Emerging technologies, such as intranasal delivery can be employed as a non-invasive option for delivering drugs and therapeutic cells to the CNS with minimal peripheral exposure. This Special Issue will gather discoveries of novel molecular targets, drugs, and biologics, as well as new delivery routes for the treatment of CNS disorders, including but not limited to Alzheimer’s disease, Parkinson’s disease, Huntington disease, depression, anxiety, autism spectrum disorders, seizures, and stroke. Short and comprehensive research papers including in vitro and in vivo studies, as well as case reports and reviews are welcome.
Dr. Lusine Danielyan
Dr. Huu Phuc Nguyen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Intranasal administration
- Stem cells
- New drug